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The Use of Protein Adducts to Investigate the
Disposition of Reactive Metabolites of Benzene
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Benzene is metabolized to a number of electrophilic species that are capable of binding to both
DNA and proteins. We used adducts of hemoglobin (Hb) and bone marrow proteins to study the
disposition of three benzene metabolites (benzene oxide [BO], 1,2-benzoquinone [1,2-BQI, and
1,4-benzoquinone [1,4-BQO) in F344 rats and B6C3F1 mice following a single oral dosage of
[13C6lbenzene and/or [14C]benzene. Our assays focused upon cysteine adducts that accounted
for 38 to 45% of protein binding to Hb and 63 to 81 % of protein binding to bone marrow.
Although both mice and rats showed dose-related increases in Hb and bone marrow protein
adducts of BO and of the two benzoquinones, large intertissue and interspecies differences were
noted, suggesting different preferences in metabolic pathways. The highest levels of adducts in
mice were of 1,4-BQ (10-27% of all cysteine adducts), while in rats, BO adducts predominated in
Hb (73% of all cysteine adducts) and 1,2-BQ adducts predominated in the bone marrow (14% of
all cysteine adducts). High background levels of 1,2-BO and 1,4-BQ adducts were also detected in
both species, indicating that the toxic effects of quinone metabolites may only be important at
high levels of benzene exposure. Environ Health Perspect 104(Suppl 6):1235-1237 (1996)
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Introduction
Benzene is a ubiquitous environmental
contaminant that is mutagenic and car-
cinogenic in various animal species includ-
ing humans. There is strong evidence that
exposures to benzene increase the risk of
leukemias, particularly ofthe acute myelo-
cytic type. However, the mechanism by
which benzene exerts its carcinogenicity
remains elusive because of the production
of numerous electrophilic metabolites.
Following inhalation, benzene is rapidly
absorbed in the blood and distributed
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throughout the body. About 50% of the
absorbed dose is eliminated unchanged in
the exhaled air (1) while the remainder is
metabolized, primarily via P4502E1,
through the electrophilic intermediate,
benzene oxide (BO), which either sponta-
neously rearranges to phenol [23-50% of
the dose; (1)] or is hydrated by epoxide
hydrolase to produce benzene-1,2-dihydro-
diol. This division ofthe two major path-
ways from BO to either phenol or the
dihydrodiol is important insofar as species
and tissue differences in P4502E1 and
epoxide hydrolases can influence the dispo-
sition ofthe reactive metabolites in animals
receiving substantial doses of benzene.
Phenol can subsequently be acted upon by
P4502E1 to produce hydroquinone (HQ)
[1-5% ofthe dose, (1)] that exists in equi-
librium with 1,4-benzoquinone (1,4-BQ)
and the associated semiquinone, both of
which are electrophiles. The dihydrodiol
can be oxidized through dehydrogenases to
catechol (CAT) [3-5% of the dose, (1)]
which also exists in equilibrium with 1,2-
benzoquinone (1,2-BQ) and its semi-
quinone. [CAT can also be produced by
P4502E1 oxidation ofphenol, but this is
considered to be a minor pathway (2).]
Finally, ring-opened products can be
formed either from oxidation ofBO (or its
oxepin) or from reactions ofbenzene with
reactive oxygen species (3) These products
include trans,trans-muconaldehyde, which
is also mutagenic and accounts for 1 to 3%
of the benzene dose (1). In addition to
these numerous electrophilic metabolites of
benzene, extensive research has also shown
that oxygen and glutathionyl free radicals
as well as products of lipid peroxidation
accompany peroxidative metabolism ofthe
phenolic metabolites; these free radical
products can also damage DNA (4).
Although research has confirmed that
most ofthe electrophilic metabolites ofben-
zene are capable offorming covalent adducts
with proteins or DNA, a major hypothesis
of benzene-induced leukemogenesis has
focused on the quinones and semiquinones
that induce mutations, either directly or
through quinone-mediated processes (5,6).
Indeed, since peroxidases are abundant in
the bone marrow, much speculation about
the carcinogenicity ofbenzene has centered
on the preferential conversion ofHQ and
CAT to the corresponding quinones in the
bone marrow (7).
Although the quinone metabolites have
been hypothesized to be important in the
genotoxicity ofbenzene, there are a number
ofenvironmental or endogenous sources of
phenol (the precursor of HQ), CAT, and
HQ (8,9). Consequently, high levels of
nonbenzene-derived quinones, and the
associated macromolecular adducts would
be expected. Indeed, we found high back-
ground levels of cysteine-bound Hb
adducts of 1,2-BQ and 1,4-benzoquinone
(1,4-BQ) in rats, mice, and humans [1-30
pmol adduct/mg Hb (10,11)].
Another important development was
the observation ofBechtold et al. (12) that
significant quantities of S-phenylcysteine
(SPC) were measured in Hb from rats and
mice exposed to benzene. The authors
attributed this SPC in the Hb to a cysteine
adduct of BO [S-(1,2-dihydro-2-hydroxy-
phenyl)-cysteine] that was presumably
rearomatized to SPC either spontaneously
or upon treatment with acid in the assay.
Although this is a plausible mechanism for
formation ofSPC, it does not preclude the
possibility of production within the red
blood cells (RBC) per se by, for example,
a cyclohexadienyldiol radical (13). If
Bechtold et al. (14) are correct in their
speculation about the origin ofSPC in Hb,
then it follows that BO (or its oxepin) is
sufficiently stable to migrate from the
hepatocyte into the systemic circulation,
where it can induce genotoxic'effects. This
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is interesting because, although BO is capa-
ble of reacting with macromolecules, we
currently have only a very sketchy under-
standing of the disposition of BO in vivo
and SPC could provide an important
avenue for such inquiries. Bechtold et al.
(12,14) also postulated that there should
be much lower background levels of BO
adducts than BQ adducts, thus making
SPC in Hb or albumin more specific
markers ofbenzene exposure.
We used assays of cysteine adducts of
BO (measured as SPC), 1,2-BQ, and 1,4-
BQ to investigate the disposition of these
electrophilic metabolites ofbenzene in rats
and mice (15). By using benzene that had
been labeled with both [14C]benzene and
[13C6]benzene, we were able to account for
the proportions oftotal protein adduction
represented by the particular adducts and
also to differentiate benzene-specific (i.e.,
[13C6]BQ or [13C6]BO adducts) from
background adducts (i.e., [12C6] adducts).
The assays were applied to proteins from
both the blood (Hb) and the bone marrow
ofthese animals.
Material and Methods
Chemicals. All chemicals and enzymes
used were the same as those described by
McDonald et al. (10,11,15).
AnimalExperiments. Ten male F344
rats were divided into five groups and were
administered a single dose of[13C6]benzene
at 0 (corn oil vehicle control), 50, 100, 200,
and 400 mg /kg bwvia gastric intubation as
described by McDonald et al. (11). Twenty
male F344 rats and 20 male B6C3Fj mice
were divided into five groups and adminis-
tered a single dosage of [14C/13C6]benzene
at 0 (corn oil vehicle control), 50, 100,
200, and 400 mg /kg bw via gastric intuba-
tion as described by McDonald et al. (15).
In both experiments the animals were
sacrificed 24 hr after dosing and blood was
obtained by cardiac puncture into a
heparinized syringe following anesthesia
with methoxyfluorane.
Analysis ofProtein Adducts. Globin
and bone marrow proteins were isolated as
described by McDonald et al. (11). Adducts
of 1,2-BQ and 1,4-BQ were analyzed by
first adding a protein-bound internal stan-
dard ([2H5]HQ-Hb ), digesting the proteins
with protease XIV, and then reacting the
proteins with the nickel-aluminum catalyst,
Raney nickel, to release the quinones from
cysteine residues on the proteins (10). After
extracting the quinone species with diethyl
ether and removing the solvent under a
stream ofnitrogen, the analytes were deriva-
tized with heptafluorobutyrylimidazole
before detection by gas chromatography-
mass spectrometry (GC-MS) in the negative
chemical ionization (NCI) mode (10).
BO-protein adducts were analyzed (as
SPC) using the method of Bechtold et al.
(14). This involved complete protein
hydrolysis followed by high performance
liquid chromatography (HPLC) separation
and collection of the fraction containing
SPC and the internal standard, S-benzyl-
cysteine. The SPC was then derivatized
and detected by GC-MS in the electron
impact mode as described by McDonald et
al. (15). The use of isotopically labeled
benzene and detection by MS allowed for
simultaneous quantitation of both ben-
zene-specific (i.e., [13C6]BQ or [13C6]BO
adducts) and background adducts (i.e.,
[12C6]BQ or [12C6]BO adducts).
Results
Proportions ofProtein Adducts. The
binding of[14C]benzene metabolites to Hb
and bone marrow proteins increased over
the range ofdosages between 50 and 400
mg/kg bw in both rats and mice (15).
Because reaction of proteins with Raney
nickel specifically cleaves adducts bound to
sulfhydryl groups, it was possible to esti-
mate the proportions ofcysteine adducts to
total protein adducts from the fractions of
radioactivity released by treatment with
Raney nickel. These proportions ofcysteine
adducts to total protein adducts were not
significantly different among the dosage
groups; thus, mean values were estimated
over all dosages. Table 1 indicates that cys-
teine binding in the blood and bone marrow
was comparable in rats and mice (38-45%
of total binding to Hb and 63-81% of
total binding to bone marrow proteins).
This large proportion of total binding to
cysteine residues points to the great reactiv-
ity of sulfhydryl groups toward elec-
trophilic metabolites ofbenzene, which can
be exploited to investigate the disposition
ofthese reactive species in vivo.
Following assays of cysteine adducts
of BO and the benzoquinones, it was
observed that levels ofall measured adducts
increased in both the blood and bone mar-
row of rats and mice over the entire range
ofdosages (15). The proportions ofpartic-
ular adducts to all cysteine adducts varied
greatly between species and proteins, as
shown in Table 2. BO adducts represented
relatively small proportions ofall cysteine
adducts (approximately 2-4%) in rat bone
marrow, mouse Hb, and mouse bone mar-
row but accounted for the majority ofcys-
teine adducts (73%) in rat Hb. Levels of
1,2-BQ adducts were highest in rat mar-
row (14% ofcysteine adducts), followed by
those in mouse Hb (6%), and in rat Hb
and mouse bone marrow (both of which
were about 1%). On the other hand,
adducts of 1,4-BQ were most prevalent in
mouse bone marrow (27% of cysteine
adducts) followed by those in rat bone
marrow (2.2-22%, depending upon the
dosage), mouse Hb (10-14%), and finally
in rat Hb (less than 1%).
BackgroundAdducts. Both 1,2-BQ
and 1,4-BQ gave rise to high levels of
background adducts, which were measured
as [1 C6]BQ adducts. The fold ranges of
these background adducts to the benzene-
specific [13C6]BQ adducts varied inversely
with dosage but were always greater than
one, even at the highest dosage of 400
mg/kg bw. As shown in Table 3, levels of
background adducts were typically 10- to
100-fold greater than those that arose from
a single dosage ofbenzene.
Discussion
The proportions ofadducts ofspecific ben-
zene metabolites shown in Table 2 point to
metabolic differences between species and
tissues. For example, the large proportion
of SPC in rat Hb (72.6%) compared to
Table 1. Proportions of [14C]benzene-protein binding
associated with cysteine adducts, mean values.a
Protein
Species Hb, % Marrow, %
Rat 37.6 63.1
Mouse 45.2 81.1
"Mean values were estimated for all dosage groups,
50 to 400 mg/kg bw.
Table 2. Proportions ofcysteine adducts arising from three electrophilic metabolites of benzene, mean values.a
Rat Mouse
Metabolite Hb, % Marrow, % Hb, % Marrow, %
Benzene oxide 72.6 4.3 3.7 1.9
1,2-Benzoquinone 1.4 13.7 5.6 0.9
1,4-Benzoquinone 0.12-0.71b 2.2-21 9b 10.0-13.6" 26.6
aMean values were estimated for all dosage groups, 50 to 400 mg/kg bw. bSignificanttrend detected with dosage;
range indicated.
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Table 3. Fold ranges of background [12C6]BQ adducts
to benzene-specific [13C6]BQ adducts at dosages of 50
to 400 mg/kg bw.
Species Protein 1,2-BQ 1,4-BQ
Rat Hb 11-68 24.7-473
Marrow 2.7-104 2.2-60
Mouse Hb 2.7-6.3 5.2-18
Marrow 160-462 1.1-6.1
that of the mouse (3.7%) suggests that
there could be large interspecies differences
regarding either the formation of BO by
the liver (and subsequent release to the
blood) or the in situ formation of BO
within the erythrocyte. On the other hand,
these differences could reflect different
rates of removal of BO within the livers of
the two species due to differences in epoxide
hydrolases and glutathione S-transferases.
Referring to adducts ofthe benzoquinones,
it appears that the pathway leading to the
formation of HQ was favored in the
mouse, whereas that leading to CAT was
favored in the rat, consistent with current
knowledge of benzene metabolism in the
two species (16).
Although levels of adducts of Hb and
bone marrow proteins of 1,2-BQ and
1,4-BQ increased with benzene dosage in
rats and mice, these levels were very small
compared to background concentrations of
the same adducts except at the highest
dosage (400 mg/kg bw). This observation is
consistent with the idea that HQ and CAT
are common dietary constituents or are
formed endogenously but casts doubt on
the notion that the phenolic metabolites
can be solely responsible for the genotoxic
effects ofbenzene, particularly at low doses.
This finding has important implications
regarding both elucidation of the mecha-
nism by which benzene induces cancer and
development ofoptimal strategies for bio-
monitoring among humans exposed to ben-
zene. If, on the one hand, the quinones or
semiquinones are responsible for the geno-
toxicity, then the risk ofcancer is likely to
be elevated only at very high levels ofben-
zene exposure, levels much greater than
those currently encountered in the United
States and other industrialized countries. If
this conjecture is correct, it is important to
know the extent ofproduction ofadducts
by the semiquinones of 1,2-BQ and
1,4-BQ, since such adducts have not been
measured heretofore and may account for a
significant amount ofthe total binding of
benzene metabolites (we can currently
account for about 20-30% of cysteine
binding in the bone marrow). It also
follows from this conjecture that measuring
adducts of the quinones is unlikely to be
useful for biomonitoring benzene exposure
because even unexposed persons have large
burdens of the same adducts (8) (we
confirmed that human Hb and albumin
also contain large background levels ofthe
BQadducts).
If, on the other hand, the quinone
species are not responsible for benzene's
genotoxicity, another metabolite is more
likely to be the culprit and the list narrows
logically to either BO or trans-trans-
muconaldehyde. We have shown that BO
produces adducts in the bone marrow of
rats and mice (albeit at levels lower than
those produced by 1,2- and 1,4-BQ in the
same animals), consistent with this conjec-
ture. It also follows that measurements of
BO adducts ofHb and albumin should be
effective biomarkers of benzene exposure
even at very low levels. In fact, Bechtold et
al. (12,14) were able to detect SPC in
albumin but not in Hb from the blood of
workers exposed to 4.4 to 23 ppm ofben-
zene. (We suspect that the sensitivity of
their assay was insufficient to detect SPC in
the Hb ofthese workers.) We are currently
using protein adducts to further elucidate
the doses ofBO received by various tissues
following administration ofbenzene.
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